Ovoca Bio plc is pleased to announce that on 1st March 2019 its subsidiary, IVIX, was granted patent No 234753 in Israel covering any use for a large list of peptide variants based on BP-101.
Ovoca Bio plc is pleased to announce that its subsidiary IVIX has commenced the process of preparing an integrated Clinical Development Plan (“CDP”) for its investigational drug candidate, Libicore (BP-101), for both the US and EU regions with Biorasi LLC (“Biorasi”), an experienced US-based contract research organization.
Ovoca Presents at BIO-Europe Spring® 2019, Vienna
|September 16, 2019||Interim Results|
|September 12, 2019||Filing of Marketing Authorisation Application with Russian Ministry of Health for BP-101|
|August 28, 2019||Directorate Change|
|June 28, 2019||Annual Report 2018|
|May 25, 2018||Annual Report 2017|
|June 30, 2017||Annual Report 2016|
|March 29, 2019||Ovoca Bio plc | Libicore Presentation|
|July 27, 2018||Ovoca Bio plc | Libicore Presentation|